Benefits
Blood pressure and blood vessel function
A meta-analysis of 11 placebo-controlled trials (387 adults, 4 to 24 g a day) found systolic blood pressure fell by about 5.4 mmHg and diastolic by 2.7 mmHg, and a later one of 22 trials found 6.4 and 2.6 mmHg. Blood vessel function (flow-mediated dilation) improved only in people whose function was low at the start. High blood pressure needs a doctor's care.
Erectile function
In a 3-month placebo-controlled trial in 98 men with blood-flow-related erection problems, 6 g a day improved erectile function scores and penile blood flow. A meta-analysis of 10 trials (540 men with mild to moderate problems, some taking arginine combinations) found better erectile scores than placebo or no treatment, while sexual desire scores did not change. Prescription PDE5 inhibitors worked better than L-arginine alone.
Aerobic capacity (VO2max)
A meta-analysis of 11 placebo-controlled trials in healthy adults, many of them athletes, taking about 2 to 12 g a day for 1 to 8 weeks found VO2max rose by only 0.07 L/min (95% CI 0.00 to 0.13), a borderline result; 6 of the 11 used arginine salts or blends. Another meta-analysis reporting larger gains drew a published critique of its calculations, so any benefit is uncertain.
Mechanism of action
Nitric Oxide Synthesis
L-arginine is converted into nitric oxide by the enzyme nitric oxide synthase (NOS) in endothelial cells, macrophages, and other tissues. This reaction also produces L-citrulline as a byproduct. Nitric oxide acts as a vasodilator, relaxing smooth muscle cells in blood vessel walls, which improves blood flow and reduces vascular resistance.
Vascular Effects
By increasing nitric oxide levels, L-arginine can relax blood vessels, which is the proposed reason for the small blood pressure changes measured in trials. Notably, the pooled trials found improved blood vessel function only in people whose function was already impaired, which fits the idea that there is less to gain when nitric oxide production is already normal. Improved oxygen delivery to tissues has not been shown in the studies cited here.
Protein and immune roles
L-arginine is a building block of proteins, and immune cells use it to make nitric oxide. These are normal body roles; taking extra arginine has not been shown in the trials summarized here to change metabolism, recovery or immunity.
Clinical trials
Multicenter, double-blind, randomized, placebo-controlled trial of 6 g/day L-arginine for 3 months (Menafra et al. 2022, J Endocrinol Invest)
98 men with blood-flow-related (vasculogenic) erectile dysfunction: 51 on L-arginine, 47 on placebo.
Relative improvements in the IIEF-6 erectile function score and in penile artery peak blood flow were significantly greater than with placebo (p<0.0001). In severe cases, the score improved but blood flow did not. Only 24% of men reached scores consistent with no erectile dysfunction. The study reported no funding; the arginine product (Bioarginina) was made by Farmaceutici Damor, from which the senior author reported occasional consulting fees outside this work. Adverse events, none clinically relevant, occurred in 5.9% on arginine and 4.3% on placebo.
Systematic review and dose-response meta-analysis of 22 randomized placebo-controlled trials (30 effect sizes) of oral L-arginine for at least 4 days (Shiraseb et al. 2022, Adv Nutr)
Adults, with and without high blood pressure, pooled across 22 RCTs.
L-arginine lowered systolic blood pressure by 6.40 mmHg (95% CI 4.05 to 8.74) and diastolic by 2.64 mmHg versus placebo. Effects were seen in normotensive and hypertensive groups, but not at doses above 9 g/day, with trials longer than 24 days, or in obese people. The effective dose for systolic pressure was 4 g/day or more.
Single-center, randomized, double-blind, placebo-controlled trial of L-arginine (goal 3 g three times daily) for 6 months added to standard care (Schulman et al. 2006, JAMA)
153 adults after a first ST-elevation heart attack.
No improvement in vascular stiffness or heart ejection fraction. Six people (8.6%) in the L-arginine group died versus none on placebo (p=0.01), and the safety committee closed enrollment. The authors concluded L-arginine should not be recommended after a heart attack.